| 1.5 -0.01 (-0.66%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.87 | 1-year : | 1.95 |
| Resists | First : | 1.6 | Second : | 1.66 |
| Pivot price | 1.54 |
|||
| Supports | First : | 1.5 | Second : | 1.24 |
| MAs | MA(5) : | 1.5 |
MA(20) : | 1.56 |
| MA(100) : | 1.72 |
MA(250) : | 2.19 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 2.9 |
D(3) : | 4.9 |
| RSI | RSI(14): 38.9 |
|||
| 52-week | High : | 3.81 | Low : | 1.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ UBX ] has closed above bottom band by 25.8%. Bollinger Bands are 48.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.52 - 1.53 | 1.53 - 1.54 |
| Low: | 1.48 - 1.49 | 1.49 - 1.5 |
| Close: | 1.49 - 1.5 | 1.5 - 1.51 |
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Mon, 15 Apr 2024
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates - Yahoo Finance
Fri, 15 Mar 2024
Is Unity Biotechnology Inc (UBX) Stock a Smart Value? - InvestorsObserver
Tue, 05 Mar 2024
Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation - Simply Wall St
Tue, 12 Dec 2023
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME - Yahoo Finance
Thu, 16 Nov 2023
Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky - Yahoo Finance
Tue, 17 Oct 2023
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 28.3 (%) |
| Shares Short | 307 (K) |
| Shares Short P.Month | 291 (K) |
| EPS | -3.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.3 % |
| Return on Equity (ttm) | -91.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -40 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.47 |
| PEG Ratio | 0 |
| Price to Book value | 0.6 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|